The stock of Adaptimmune Therapeutics Plc Ads (NASDAQ:ADAP) registered a decrease of 7% in short interest. ADAP’s total short interest was 1.03 million shares in April as published by FINRA. Its down 7% from 1.11 million shares, reported previously. With 235,400 shares average volume, it will take short sellers 4 days to cover their ADAP’s short positions. The short interest to Adaptimmune Therapeutics Plc Ads’s float is 2.7%. The stock decreased 1.70% or $0.17 on April 8, hitting $9.82. Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) has declined 14.98% since September 2, 2015 and is downtrending. It has underperformed by 20.04% the S&P500.
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The company has a market cap of $686.59 million. The Firm is focused on cancer immunotherapy products based on its T-cell receptor platform. It currently has negative earnings. The Firm has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients.
Adaptimmune Therapeutics PLC - ADR - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.
